Luyan Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Operating Revenue	21,367	21,189	20,398	19,785	19,406	17,508
Other Revenue	57.35	57.35	72.73	60.56	56.58	37.16
Revenue	21,424	21,247	20,471	19,846	19,463	17,545
Revenue Growth (YoY)	4.46%	3.79%	3.15%	1.97%	10.93%	12.94%
Cost of Revenue	19,930	19,749	18,948	18,339	17,950	16,179
Gross Profit	1,495	1,497	1,523	1,506	1,512	1,366
Selling, General & Admin	860.06	849.34	789.17	750.99	731.55	701.2
Research & Development	6.99	6.52	5.85	5.53	4.15	2.97
Other Operating Expenses	54.19	53.47	46.9	42.15	41.59	37.85
Operating Expenses	921.45	920.25	838.39	811.62	809.68	765.63
Operating Income	573.09	577.17	684.26	694.86	702.35	600.39
Interest Expense	-169.81	-178.36	-206.68	-222.85	-219.1	-190.28
Interest & Investment Income	2.94	2.66	3.84	5.14	3.86	5.18
Currency Exchange Gain (Loss)	0.77	0.77	-0.95	-0.03	0.1	0.01
Other Non Operating Income (Expenses)	-14.28	-12.52	-12.08	-6.95	-22.91	-13.14
EBT Excluding Unusual Items	392.71	389.72	468.38	470.16	464.3	402.15
Impairment of Goodwill	-	-	-	-	-	-1.89
Gain (Loss) on Sale of Investments	-18.91	-14.33	-18.73	-12.16	-6.92	-2.14
Gain (Loss) on Sale of Assets	-0.42	0.26	0.17	0.28	0.13	-0.53
Asset Writedown	-0.47	-0.44	-0.09	-0.13	-0.03	-1.7
Other Unusual Items	0.96	1.01	3.53	11.27	8.54	19.33
Pretax Income	373.87	376.23	453.27	469.42	466.01	415.22
Income Tax Expense	98.61	97.25	105.58	104.93	115.04	110.6
Earnings From Continuing Operations	275.27	278.98	347.7	364.49	350.97	304.61
Minority Interest in Earnings	2.23	1.9	-2.05	-0.96	-5.82	1.26
Net Income	277.5	280.88	345.64	363.53	345.16	305.87
Net Income to Common	277.5	280.88	345.64	363.53	345.16	305.87
Net Income Growth	-16.72%	-18.74%	-4.92%	5.32%	12.84%	14.72%
Shares Outstanding (Basic)	391	390	388	387	388	387
Shares Outstanding (Diluted)	391	390	388	387	388	387
Shares Change (YoY)	-0.32%	0.45%	0.42%	-0.28%	0.17%	7.46%
EPS (Basic)	0.71	0.72	0.89	0.94	0.89	0.79
EPS (Diluted)	0.71	0.72	0.89	0.94	0.89	0.79
EPS Growth	-16.45%	-19.10%	-5.32%	5.62%	12.66%	6.76%
Free Cash Flow	308.03	454.66	216.36	779.91	-95.4	-615.51
Free Cash Flow Per Share	0.79	1.17	0.56	2.02	-0.25	-1.59
Dividend Per Share	0.350	0.350	0.350	0.300	0.300	0.300
Dividend Growth	-	-	16.67%	-	-	50.00%
Gross Margin	6.98%	7.05%	7.44%	7.59%	7.77%	7.79%
Operating Margin	2.67%	2.72%	3.34%	3.50%	3.61%	3.42%
Profit Margin	1.29%	1.32%	1.69%	1.83%	1.77%	1.74%
Free Cash Flow Margin	1.44%	2.14%	1.06%	3.93%	-0.49%	-3.51%
EBITDA	647.26	650.21	752.83	753.71	757.8	654.87
EBITDA Margin	3.02%	3.06%	3.68%	3.80%	3.89%	3.73%
D&A For EBITDA	74.16	73.04	68.57	58.85	55.45	54.48
EBIT	573.09	577.17	684.26	694.86	702.35	600.39
EBIT Margin	2.67%	2.72%	3.34%	3.50%	3.61%	3.42%
Effective Tax Rate	26.37%	25.85%	23.29%	22.35%	24.69%	26.64%
Revenue as Reported	21,424	21,247	20,471	19,846	19,463	17,545
Advertising Expenses	-	3.99	5.53	1.27	1.94	1.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.